Since myeloma treatment, particularly stem cell transplantation, has immune-modulating properties, we finally investigated the relationship between therapeutic interventions and the occurrence of SOX2-specific antibodies in the myeloma patients. This evidence concerns the gene SOX2 and plasma cell myeloma.